Filip Janku Biography and Net Worth

Filip joined Monte Rosa Therapeutics from The University of Texas MD Anderson Cancer Center, where he served as a Medical Oncologist and Associate Professor in the Department of Investigational Cancer Therapeutics and the Center Medical Director for the Clinical and Translational Research Center. Filip brings expertise in innovative early-phase clinical development of new cancer drugs with a special focus on proof-of-concept clinical studies of novel, biomarker-driven, personalized therapies. Filip’s work has been recognized with multiple awards including the Emil Frei, III Award for Excellence in Translational Research, Sabin Family Fellow Award, Khalifa Scholar Award, Sidney Kimmel Scholar Award; and he authored or co-authored over 290 scientific articles in peer-reviewed journals. Filip received his M.D. and Ph.D. from Charles University Prague in the Czech Republic. He completed his medical training at the same institution and at The University of Texas MD Anderson Cancer Center.

What is Filip Janku's net worth?: The estimated net worth of Filip Janku is at least $960.09 thousand as of June 30th, 2026. Mr. Janku owns 60,612 shares of Monte Rosa Therapeutics stock worth more than $960,094 as of August 13th. This net worth estimate does not reflect any other investments that Mr. Janku may own. Learn More about Filip Janku's net worth.
How do I contact Filip Janku?: The corporate mailing address for Mr. Janku and other Monte Rosa Therapeutics executives is , , . Monte Rosa Therapeutics can also be reached via phone at 617-949-2643 and via email at [email protected]. Learn More on Filip Janku's contact information.
Has Filip Janku been buying or selling shares of Monte Rosa Therapeutics?: Filip Janku has not been actively trading shares of Monte Rosa Therapeutics in the last ninety days. Most recently, Filip Janku sold 5,407 shares of the business's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $24.50, for a transaction totalling $132,471.50. Following the completion of the sale, the insider now directly owns 60,612 shares of the company's stock, valued at $1,484,994. Learn More on Filip Janku's trading history.
Who are Monte Rosa Therapeutics' active insiders?: Monte Rosa Therapeutics' insider roster includes Jennifer Champoux (COO), Filip Janku (Insider), Filip Janku (Insider), Anthony Manning (Director), Philip Nickson (Insider), Sharon Townson (Insider), and Markus Warmuth (CEO). Learn More on Monte Rosa Therapeutics' active insiders.
Are insiders buying or selling shares of Monte Rosa Therapeutics?: During the last twelve months, insiders at the sold shares 17 times. They sold a total of 124,394 shares worth more than $2,565,671.35. The most recent insider tranaction occured on July, 6th when insider Sharon Townson sold 6,000 shares worth more than $139,860.00. Insiders at Monte Rosa Therapeutics own 6.4% of the company. Learn More about insider trades at Monte Rosa Therapeutics.
Information on this page was last updated on 7/6/2026.

Filip Janku Insider Trading History at Monte Rosa Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/30/2026	Sell	5,407	$24.50	$132,471.50	60,612
6/29/2026	Sell	6,000	$22.95	$137,700.00	59,992
6/24/2026	Sell	30,000	$21.42	$642,600.00	59,992
6/23/2026	Sell	11,845	$20.22	$239,505.90	59,992

Filip Janku Buying and Selling Activity at Monte Rosa Therapeutics

Monte Rosa Therapeutics Company Overview

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $15.84

$15.79

$16.25

50 Day Range

MA: $20.38

$15.38

$24.56

2 Week Range

Now: $15.84

$4.30

$25.77

Volume

682,349 shs

Average Volume

1,390,882 shs

Market Capitalization

$1.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59